Current Report Filing (8-k)
February 22 2022 - 4:47PM
Edgar (US Regulatory)
0001441693
false
0001441693
2022-02-15
2022-02-15
0001441693
dei:FormerAddressMember
2022-02-15
2022-02-15
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
WASHINGTON,
DC 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of the
Securities
Exchange Act of 1934
Date
of report (Date of earliest event reported): February 15, 2022
MARRONE
BIO INNOVATIONS, INC.
(Exact
Name of Registrant as Specified in Charter)
Delaware |
|
001-36030 |
|
20-5137161 |
(State
or Other Jurisdiction
of
Incorporation) |
|
(Commission
File
Number) |
|
(I.R.S.
Employer
Identification
No.) |
7780-420
Briar Creek Parkway, Raleigh, NC 27617
(Address
of Principal Executive Offices, and Zip Code)
(530)
750-2800
Registrant’s
Telephone Number, Including Area Code
1540
Drew Avenue, Davis, CA 95618
(Former
Name or Former Address, if Changed Since Last Report)
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under
any of the following provisions (see General Instruction A.2. below):
|
☐ |
Written
communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
|
|
|
|
☐ |
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
|
|
|
|
|
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
|
|
|
|
☐ |
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities
registered pursuant to Section 12(b) of the Act:
Title
of each class |
|
Trading
Symbol(s) |
|
Name
of each exchange on which registered |
Common
Stock, $0.00001 par value |
|
MBII |
|
Nasdaq
Capital Market |
Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405
of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2 of this chapter).
Emerging
growth company ☐
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item
5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of
Certain Officers.
On
February 15, 2022, Suping (Sue) Cheung notified Marrone Bio Innovations, Inc. (the “Company”) of her decision to resign from
her position as the Company’s Chief Financial Officer, effective March 9, 2022, for personal reasons.
On
February 21, 2022, the Company’s board of directors approved the retention of LaDon Johnson as Interim Chief Financial Officer,
effective upon Ms. Cheung’s departure, under an agreement with CFO Systems, LLC (“CFO Systems”), a provider of senior
financial and accounting executive and support services. Mr. Johnson will also serve as our principal financial and accounting officer
until we appoint a permanent successor to Ms. Cheung. We have agreed to pay CFO Systems an hourly fee of $325 for the services
of Mr. Johnson.
Mr.
Johnson, 60, is an experienced senior executive bringing extensive international business acumen in finance, strategy, business
development, mergers & acquisitions, and operations to the Company. He currently serves as a director at CFO Systems, where he has
worked since August 2017. Previously, Mr. Johnson worked for over a decade from 2006 through 2017 as a business and financial advisor
and consultant to companies in the biotechnology, crop sciences, food and agriculture industries, including service as President and
Chief Financial Officer of Icicle Seafoods, Inc. from July 2014 through August 2016 and service as Managing Director of Cibus Europe
BV and Chief Financial Officer of Cibus Global, Ltd. from December 2008 to June 2014. Mr. Johnson has a B.S. in Accounting from Iowa
State University’s Ivy College of Business.
There
are no arrangements or understandings between Mr. Johnson and any other person pursuant to which Mr. Johnson was appointed to serve as
Interim Chief Financial Officer of the Company. There are no family relationships between Mr. Johnson and any director or executive officer
of the Company, and Mr. Johnson does not have any direct or indirect material interest in any transaction required to be disclosed pursuant
to Item 404(a) of Regulation S-K.
On
February 22, 2022, the Company issued a press release announcing the departure of Ms. Cheung and appointment of Mr. Johnson. A copy of
the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K.
Item
9.01. Financial Statements and Exhibits.
|
(d)
Exhibits. |
|
|
|
|
99.1 |
Press release. |
|
|
|
|
104 |
Cover
Page Interactive Data File (embedded within the Inline XBRL document). |
Signature
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.
|
MARRONE
BIO INNOVATIONS, INC. |
|
|
Date:
February 22, 2022 |
By: |
/s/
Linda V. Moore |
|
Name: |
Linda
V. Moore |
|
Title: |
Chief
Legal Officer |
Marrone Bio Innovations (NASDAQ:MBII)
Historical Stock Chart
From Jun 2024 to Jul 2024
Marrone Bio Innovations (NASDAQ:MBII)
Historical Stock Chart
From Jul 2023 to Jul 2024